Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
Date:12/6/2010

ming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,500 people with HAE in the United States.

For more information on HAE, visit the U.S. HAE Association's website at: www.haea.org, and the International HAE Association's website at: www.haei.org.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile infection.

ViroPharma routinely posts information, including press releases, which may be important to investors in the
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
2. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
3. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
4. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
6. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
9. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
10. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
11. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... China, Aug. 25, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ... a leading pharmaceutical company specializing in the development, manufacturing, ... China, today announced that it has received the new ... ("SFDA") for Iremod. Iremod, which was independently ...
... Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN ) announced today ... conducted multiple clinical studies of zinc lozenges for the common cold, ... Eby is a pioneer in the development of zinc lozenges as ... 30 years to the study of zinc and is the executive ...
Cached Medicine Technology:Simcere's Iremod Receives SFDA New Drug Approval 2Adeona Appoints George A. Eby to Scientific Advisory Board 2Adeona Appoints George A. Eby to Scientific Advisory Board 3Adeona Appoints George A. Eby to Scientific Advisory Board 4
(Date:7/9/2014)... Susan Wakulich was told she had an aneurysm, she figured ... her. , "I was devastated," said Wakulich, who is 56 ... this was a serious diagnosis. Then I met Dr. Bernard ... a less invasive procedure. It was something I didn,t even ... a multi-center U.S. clinical trial to evaluate the safety and ...
(Date:7/9/2014)... Fox Chase Cancer Center paint a relatively optimistic picture ... cancers that have spread to the chest wall or ... into the skin, regardless of size and whether they ... III and called "locally advanced" tumors, suggesting that ... with poor survival. Locally advanced breast cancers of this ...
(Date:7/9/2014)... available in French . ... year old teens, including brain structure and function, personality, life ... will go on to develop binge drinking within the next ... other variables such as life events and a family history ... Whether or not the child had had a single ...
(Date:7/9/2014)... for being highly toxic, but when used in the right ... offer potential health benefits in a range of issues, from ... (AP39), designed and made at the University of Exeter, could ... very small amounts of the substance to the right (or ... already found that the compound protects mitochondria the "powerhouse" ...
(Date:7/9/2014)... Previous studies linking older age with kidney and heart ... kidney donation among older adults. However, in the first ... the Perelman School of Medicine at the University of ... above) enjoy similar life expectancy and cardiovascular health as ... kidneys. In light of the ever increasing organ transplant ...
Breaking Medicine News(10 mins):Health News:New type of stent could help some brain aneurysm patients 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:What drives a child to abuse alcohol? 2Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2
... WASHINGTONThe rezoning around a planned light rail line in the ... the health of the people in the communities it would ... today by PolicyLink, TakeAction Minnesota, and ISAIAH, a nonprofit coalition ... Paul and St. Cloud region. The HIA was made possible ...
... An investigational vaccine protected some women against infection from one of ... according to findings in the New England Journal of Medicine ... virus type 1 (HSV-1), but did not protect women from herpes ... of the cases of genital herpes caused by HSV-1 58 ...
... WEDNESDAY, Jan. 4 (HealthDay News) -- Some people with advanced ... a mutation in the so-called TFAP2E gene may play a ... Knowing which patients carry the mutation might help doctors tailor ... "In our study, we identified a gene which is ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... in the United States has jumped by 76 percent since ... increase appears linked to new fertility treatments that make it ... released by the U.S. Centers for Disease Control and Prevention. ...
... 4, 2012 -- ,CHAPEL HILL People with high cholesterol ... plaques within their arteries can rupture triggering the formation of ... the blood supply to their heart or brain. ... clotting. Now, a study led by researchers from the University ...
... quality of life higher in cancer survivors who exercise, ... though most doctors recommend exercise, many patients fail ... University of Colorado Cancer Center, recently published in the ... by the American College of Sports Medicine, makes planning ...
Cached Medicine News:Health News:Twin Cities light rail project presents both opportunities and risks for health, according to report 2Health News:Twin Cities light rail project presents both opportunities and risks for health, according to report 3Health News:Research shows progress toward a genital herpes vaccine 2Health News:Research shows progress toward a genital herpes vaccine 3Health News:Gene Mutation Linked to Chemo-Resistant Colon Cancer 2Health News:U.S. Twin Births Soar: CDC 2Health News:U.S. Twin Births Soar: CDC 3Health News:Benefits of statin therapy may extend beyond lowering lipids 2Health News:Downloadable tool helps cancer survivors plan and monitor exercise 2
Neuropack Sigma MEB-5500 series evoked potential measuring system is a compact, portable, all-in-one unit....
The Nicolet Bravo is a Multi-application system that can configure to meet the needs of neurophysiology deparent....
... systems of the MYOHANDY family are ... the MYOQUICK - SystemPLUS line. Based ... acquisition systems of the ISA 100x ... 1002, ISA 1002 EP) , 4 ...
... The new line of Myoquick systemplus Multi-channels ... excellence of Micromed in the neurophysiology field and ... company. Multi-channel EP unit adopt the 32 channels ... systems of the ISA 100x EP family headboxes: ...
Medicine Products: